A DNA-based coronavirus vaccine is being developed by GeoVax, in collaboration with Bravovax, for the prevention of coronavirus disease 2019 (COVID-2019) infections. Geovax is using its modified vaccinia ankara-virus-like particles (MVA-VLP/GV-MVA-VLPTM) platform, which generates non-infectious VLPs, mimicking a natural infection to trigger the body of an individual being vaccinated to produce a robust and durable immune response with both antibodies and T cells. The company has designed, constructed, and characterised three vaccine candidates, of which one will be selected in accordance with results from preclinical studies. Early research is underway in the US.
In January 2020, GeoVax entered into a research and development agreement with BravoVax for the development vaccine against COVID-2019 infections. Unders the terms of agreement, GeoVax will utilise its MVA-VLP vaccine platform and expertise to design and construct the vaccine using genetic sequences from the ongoing coronavirus. BravoVax will provide further development, including testing and manufacturing support, as well as direct interactions with Chinese public health and regulatory authorities. 
Key Development Milestones
GeoVax Labs plans to initiate human clinical trial before the end of 2020  .
In March 2020, GeoVax reported that it plans to conduct preclinical studies of three vaccine candidates for prevention of COVID-2019 infections  .